Boehringer Ingelheim’s CHF450 Million Acquisition of T3 Pharmaceuticals AG

Walder Wyss advised Boehringer Ingelheim in the transaction. Boehringer Ingelheim announced the acquisition of privately-held T3 Pharmaceuticals AG, a clinical stage Swiss biotech company, for an…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Author: Marco Zingaro

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here